| Literature DB >> 34477024 |
Jan Philipp Bewersdorf1, Andriy Derkach2, Lohith Gowda1, Kamal Menghrajani3,4, Susan DeWolf3, Josel D Ruiz5, Doris M Ponce4,5, Brian C Shaffer4,5, Roni Tamari4,5, James W Young4,5,6, Ann A Jakubowski4,5, Boglarka Gyurkocza4,5, Alexander Chan7, Wenbin Xiao7, Jacob Glass3,4, Amber C King8, Sheng F Cai3,4, Anthony Daniyan3,4, Christopher Famulare3, Bernadette M Cuello3, Nikolai A Podoltsev1, Mikhail Roshal7, Sergio Giralt4,5, Miguel-Angel Perales4,5, Stuart Seropian1, Christina Cho4,5, Amer M Zeidan1, Thomas Prebet1, Eytan M Stein3,4, Martin S Tallman3,4, Aaron D Goldberg3,4, Maximilian Stahl3,4.
Abstract
The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We conducted a retrospective study of patients with AML or myelodysplastic syndrome (MDS) who received venetoclax either before or after allo-HCT at Memorial Sloan Kettering Cancer Center and Yale University from 11 August 2016 to 16 November 2020. Among 39 heavily pretreated patients who received venetoclax before allo-HCT, median OS from allo-HCT was not reached after a median follow up of 12.5 months resulting in a 12-month OS estimate of 79.0%. In 37 patients who had received venetoclax-based combinations as salvage therapy after allo-HCT, the overall response rate was 32% with a median OS of 4.7 months (12-month OS estimate: 43.4%). Four patients underwent a second allo-HCT following venetoclax-based salvage therapy suggesting it as a potential salvage treatment option.Entities:
Keywords: AML; Acute myeloid leukemia; MDS; transplant; venetoclax
Mesh：
Substances：
Year: 2021 PMID： 34477024 PMCID： PMC9012492 DOI： 10.1080/10428194.2021.1966788
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022